Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialKohei Shitara, Jaffer A. Ajani, Eric Van Cutsem et al.|The Lancet|2023Cited by 701
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trialManish A. Shah, Rui‐Hua Xu, Kohei Shitara et al.|Nature Medicine|2023Cited by 541
Puromycin-based vectors promote a ROS-dependent recruitment of PML to nuclear inclusions enriched with HSP70 and ProteasomesDiarmuid Moran, Carl G. Maki|BMC Cell Biology|2009Cited by 25